Efficacy of chemotherapy for patients with metastatic or recurrent pancreatic adenosquamous carcinoma: A multicenter retrospective analysis

被引:5
作者
Yoshida, Yukio [1 ,26 ]
Kobayashi, Satoshi [2 ]
Ueno, Makoto [2 ]
Morizane, Chigusa [3 ]
Tsuji, Kunihiro [4 ]
Maruki, Yuta [3 ]
Mori, Keita [5 ]
Watanabe, Kazuo [6 ]
Ohba, Akihiro [3 ]
Furuta, Mitsuhiro [2 ,7 ]
Todaka, Akiko [7 ]
Tsujimoto, Akiko [8 ]
Ozaka, Masato [9 ]
Okano, Naohiro [10 ]
Yane, Kei [11 ]
Umemoto, Kumiko [11 ,12 ]
Kawamoto, Yasuyuki [12 ,13 ]
Terashima, Takeshi [13 ,14 ]
Tsumura, Hidetaka [15 ]
Doi, Keitaro [15 ,16 ]
Shioji, Kazuhiko [16 ,17 ]
Asagi, Akinori [17 ,18 ]
Kojima, Yasushi [18 ,19 ]
Suzuki, Eiichiro [19 ,20 ]
Toshiyama, Reishi [20 ,21 ]
Furukawa, Masayuki [21 ,22 ]
Naganuma, Atsushi [22 ,23 ]
Suzuki, Rei [23 ,24 ]
Miwa, Haruo [24 ,25 ]
Ikeda, Masafumi [6 ]
Furuse, Junji [2 ,9 ]
机构
[1] Okinawa Chubu Hosp, Div Oncol & Hematol, Okinawa, Japan
[2] Kanagawa Canc Ctr, Dept Gastroenterol, Yokohama, Japan
[3] Natl Canc Ctr, Dept Hepatobiliary & Pancreat Oncol, Tokyo, Japan
[4] Ishikawa Prefectural Cent Hosp, Dept Gastroenterol, Ishikawa, Japan
[5] Clin Res Support Ctr, Shizuoka Canc Ctr, Dept Biostat, Shizuoka, Japan
[6] Natl Canc Ctr Hosp East, Dept Hepatobiliary & Pancreat Oncol, Kashiwa, Japan
[7] Shizuoka Canc Ctr, Div Gastrointestinal Oncol, Shizuoka, Japan
[8] Chiba Canc Ctr, Div Gastroenterol, Chiba, Japan
[9] Japanese Fdn Canc Res, Hepatobiliary Pancreat Med Dept, Canc Inst Hosp, Tokyo, Japan
[10] Kyorin Univ Fac Med, Dept Med Oncol, Tokyo, Japan
[11] Teine Keijinkai Hosp, Ctr Gastroenterol, Sapporo, Japan
[12] St Marianna Univ Sch Med, Dept Clin Oncol, Kawasaki, Japan
[13] Hokkaido Univ Hosp, Div Canc Ctr, Sapporo, Japan
[14] Kanazawa Univ, Dept Gastroenterol, Kanazawa, Japan
[15] Hyogo Canc Ctr, Dept Gastroenterol Oncol, Akashi, Hyogo, Japan
[16] Kyoto Univ, Grad Sch Med, Dept Therapeut Oncol, Kyoto, Japan
[17] Niigata Canc Ctr Hosp, Dept Internal Med, Niigata, Japan
[18] Natl Hosp Org Shikoku Canc Ctr, Dept Gastrointestinal Med Oncol, Matsuyama, Japan
[19] Natl Ctr Global Hlth & Med, Dept Gastroenterol, Tokyo, Japan
[20] Chiba Univ, Grad Sch Med, Dept Gastroenterol & Nephrol, Chiba, Japan
[21] Natl Hosp Org Osaka Natl Hosp, Dept Surg, Osaka, Japan
[22] Natl Hosp Org Kyushu Canc Ctr, Dept Hepatobiliary Pancreatol, Fukuoka, Japan
[23] Natl Hosp Org Takasaki Gen Med Ctr, Dept Gastroenterol, Takasaki, Japan
[24] Fukushima Med Univ, Sch Med, Dept Gastroenterol, Fukushima, Japan
[25] Yokohama City Univ Med Ctr, Gastroenterol Ctr, Yokohama, Japan
[26] Okinawa Chubu Hosp, Div Oncol & Hematol, 281 Miyazato, Uruma, Okinawa 9042293, Japan
关键词
Pancreatic cancer; FOLFIRINOX; Gemcitabine; Nab-paclitaxel; Pancreatic adenosquamous carcinoma; PACLITAXEL PLUS GEMCITABINE; NAIVE JAPANESE PATIENTS; PHASE-II; CANCER; FOLFIRINOX; PROGNOSIS;
D O I
10.1016/j.pan.2022.09.236
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background/objectives: Pancreatic adenosquamous carcinoma (PASC) is a rare variant of pancreatic ductal adenocarcinoma (PDAC). The usual treatment for metastatic or recurrent PASC is systemic chemotherapy in accordance with the PDAC treatment strategy. This study aimed to investigate the efficacy of chemotherapy, especially the benefit of recent combination therapies, in patients with metastatic or recurrent PASC.Methods: We conducted a multicenter retrospective analysis of 116 patients with metastatic or recurrent PASC treated with first-line chemotherapy between April 2001 and December 2017 at 24 Japanese institutions.Results: Combination chemotherapies included gemcitabine + nab-paclitaxel (GnP, n = 28), fluorouracil/ leucovorin + irinotecan + oxaliplatin (FFX, n = 10), gemcitabine + S-1 (GS, n = 10), and others (n = 9). Monotherapies included gemcitabine (n = 51) and S-1 (n = 8). The median overall survival (OS) was 6.5, 7.3, and 4.3 months for the whole cohort, the combination therapy group, and the monotherapy group, respectively. Multivariate analysis indicated that combination therapy showed a better trend in OS than monotherapy (hazard ratio = 0.68; 95% confidence interval, 0.38-1.20). GnP or FFX were selected in 58.7% of patients after FFX was approved in Japan, and revealed a median OS, median progression-free survival, and objective response rate of 7.3 months, 2.8 months, and 26.9% in GnP and 7.2 months, 2.3 months, and 20.0% in FFX respectively.Conclusions: This study suggests that combination therapy may be more effective than monotherapy. GnP and FFX showed similar and clinically meaningful efficacy for patients with metastatic or recurrent PASC.(c) 2022 IAP and EPC. Published by Elsevier B.V. All rights reserved.
引用
收藏
页码:1159 / 1166
页数:8
相关论文
共 25 条
  • [1] 415 Patients with Adenosquamous Carcinoma of the Pancreas: A Population-Based Analysis of Prognosis and Survival
    Boyd, Casey A.
    Benarroch-Gampel, Jaime
    Sheffield, Kristin M.
    Cooksley, Catherine D.
    Riall, Taylor S.
    [J]. JOURNAL OF SURGICAL RESEARCH, 2012, 174 (01) : 12 - 19
  • [2] Systemic Chemotherapy for Advanced Rare Pancreatic Histotype Tumors: A Retrospective Multicenter Analysis
    Brunetti, Oronzo
    Aprile, Giuseppe
    Marchetti, Paolo
    Vasile, Enrico
    Gardini, Andrea Casadei
    Scartozzi, Mario
    Barni, Sandro
    Delfanti, Sara
    De Vita, Fernando
    Di Costanzo, Francesco
    Milella, Michele
    Cella, Chiara Alessandra
    Berardi, Rossana
    Cataldo, Ivana
    Scarpa, Aldo
    Basile, Debora
    Mazzuca, Federica
    Graziano, Giusi
    Argentiero, Antonella
    Santini, Daniele
    Reni, Michele
    Cascinu, Stefano
    Silvestris, Nicola
    [J]. PANCREAS, 2018, 47 (06) : 759 - 771
  • [3] Real-world comparative effectiveness of nab-paclitaxel plus gemcitabine versus FOLFIRINOX in advanced pancreatic cancer: a systematic review
    Chiorean, Elena Gabriela
    Cheung, Winston Y.
    Giordano, Guido
    Kim, George
    Al-Batran, Salah-Eddin
    [J]. THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2019, 11
  • [4] FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
    Conroy, Thierry
    Desseigne, Francoise
    Ychou, Marc
    Bouche, Olivier
    Guimbaud, Rosine
    Becouarn, Yves
    Adenis, Antoine
    Raoul, Jean-Luc
    Gourgou-Bourgade, Sophie
    de la Fouchardiere, Christelle
    Bennouna, Jaafar
    Bachet, Jean-Baptiste
    Khemissa-Akouz, Faiza
    Pere-Verge, Denis
    Delbaldo, Catherine
    Assenat, Eric
    Chauffert, Bruno
    Michel, Pierre
    Montoto-Grillot, Christine
    Ducreux, Michel
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2011, 364 (19) : 1817 - 1825
  • [5] Adenosquamous Carcinoma of the Pancreas
    Del Arco, Helene
    Chakiba-Brugere, Camille
    Salabert, Laura
    Bechade, Dominique
    [J]. CLINICAL MEDICINE INSIGHTS-ONCOLOGY, 2019, 13
  • [6] Comparative outcomes of adenosquamous carcinoma of the pancreas: An analysis of the National Cancer Database
    Hester, Caitlin A.
    Augustine, Mathew M.
    Choti, Michael A.
    Mansour, John C.
    Minter, Rebecca M.
    Polanco, Patricio M.
    Porembka, Matthew R.
    Wang, Sam C.
    Yopp, Adam C.
    [J]. JOURNAL OF SURGICAL ONCOLOGY, 2018, 118 (01) : 21 - 30
  • [7] Clinical Characteristics of Adenosquamous Carcinoma of the Pancreas A Matched Case-Control Study
    Imaoka, Hiroshi
    Shimizu, Yasuhiro
    Mizuno, Nobumasa
    Hara, Kazuo
    Hijioka, Susumu
    Tajika, Masahiro
    Kondo, Shinya
    Tanaka, Tsutomu
    Ogura, Takeshi
    Obayashi, Tomohiko
    Hasegawa, Toshiyuki
    Niwa, Yasumasa
    Yamao, Kenji
    [J]. PANCREAS, 2014, 43 (02) : 287 - 290
  • [8] Randomized phase II study of chemoradiotherapy with versus without induction chemotherapy for locally advanced pancreatic cancer: Japan Clinical Oncology Group trial, JCOG1106
    Ioka, Tatsuya
    Furuse, Junji
    Fukutomi, Akira
    Mizusawa, Junki
    Nakamura, Satoaki
    Hiraoka, Nobuyoshi
    Ito, Yoshinori
    Katayama, Hiroshi
    Ueno, Makoto
    Ikeda, Masafumi
    Sugimori, Kazuya
    Okano, Naohiro
    Shimizu, Kyoko
    Yanagimoto, Hiroaki
    Okusaka, Takuji
    Ozaka, Masato
    Todaka, Akiko
    Nakamori, Shoji
    Tobimatsu, Kazutoshi
    Sata, Naohiro
    Kawashima, Yohei
    Hosokawa, Ayumu
    Yamaguchi, Taketo
    Miyakawa, Hiroyuki
    Hara, Hiroki
    Mizuno, Nobumasa
    Ishii, Hiroshi
    [J]. JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2021, 51 (02) : 235 - 243
  • [9] Clinical presentation and prognosis of adenosquamous carcinoma of the pancreas-Matched-pair analysis with pancreatic ductal adenocarcinoma
    Kaiser, Joerg
    Hinz, Ulf
    Mayer, Philipp
    Hank, Thomas
    Niesen, Willem
    Hackert, Thilo
    Gaida, Matthias M.
    Buechler, Markus W.
    Strobel, Oliver
    [J]. EJSO, 2021, 47 (07): : 1734 - 1741
  • [10] Investigation of the freely available easy-to-use software 'EZR' for medical statistics
    Kanda, Y.
    [J]. BONE MARROW TRANSPLANTATION, 2013, 48 (03) : 452 - 458